Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 38 entries
Sorted by: Best Match Show Resources per page
Use of biologic mesh at ostomy takedown to prevent incisional hernia: A case series.

International journal of surgery case reports

Lalezari S, Caparelli ML, Allamaneni S.
PMID: 29059608
Int J Surg Case Rep. 2017;41:107-109. doi: 10.1016/j.ijscr.2017.10.002. Epub 2017 Oct 06.

INTRODUCTION: Incisional hernias are a relatively common occurrence after ostomy takedown with a incidence of 30-35%. The use of biologic mesh offers a means to bolster the stoma incision site with a lower risk of infection than synthetic mesh.METHODS:...

Cite
Lalezari S, Caparelli ML, Allamaneni S. Use of biologic mesh at ostomy takedown to prevent incisional hernia: A case series. Int J Surg Case Rep. 2017;41:107-109doi: 10.1016/j.ijscr.2017.10.002.
Lalezari, S., Caparelli, M. L., & Allamaneni, S. (2017). Use of biologic mesh at ostomy takedown to prevent incisional hernia: A case series. International journal of surgery case reports, 41107-109. https://doi.org/10.1016/j.ijscr.2017.10.002
Lalezari, Sepehr, et al. "Use of biologic mesh at ostomy takedown to prevent incisional hernia: A case series." International journal of surgery case reports vol. 41 (2017): 107-109. doi: https://doi.org/10.1016/j.ijscr.2017.10.002
Lalezari S, Caparelli ML, Allamaneni S. Use of biologic mesh at ostomy takedown to prevent incisional hernia: A case series. Int J Surg Case Rep. 2017;41:107-109. doi: 10.1016/j.ijscr.2017.10.002. Epub 2017 Oct 06. PMID: 29059608; PMCID: PMC5651556.
Copy Download .nbib Format: NLM
Evaluation of fully covered self-expanding metal stents in benign biliary strictures and bile leaks.

World journal of gastrointestinal endoscopy

Lalezari D, Singh I, Reicher S, Eysselein VE.
PMID: 23858377
World J Gastrointest Endosc. 2013 Jul 16;5(7):332-9. doi: 10.4253/wjge.v5.i7.332.

AIM: To investigate the use of fully covered metal stents in benign biliary strictures (BBS) and bile leaks.METHODS: We studied 17 patients, at Harbor-UCLA Medical center (Los Angeles), with BBS (n = 12) and bile leaks (n = 5)...

Cite
Lalezari D, Singh I, Reicher S, et al. Evaluation of fully covered self-expanding metal stents in benign biliary strictures and bile leaks. World J Gastrointest Endosc. 2013;5(7):332-9doi: 10.4253/wjge.v5.i7.332.
Lalezari, D., Singh, I., Reicher, S., & Eysselein, V. E. (2013). Evaluation of fully covered self-expanding metal stents in benign biliary strictures and bile leaks. World journal of gastrointestinal endoscopy, 5(7), 332-9. https://doi.org/10.4253/wjge.v5.i7.332
Lalezari, David, et al. "Evaluation of fully covered self-expanding metal stents in benign biliary strictures and bile leaks." World journal of gastrointestinal endoscopy vol. 5,7 (2013): 332-9. doi: https://doi.org/10.4253/wjge.v5.i7.332
Lalezari D, Singh I, Reicher S, Eysselein VE. Evaluation of fully covered self-expanding metal stents in benign biliary strictures and bile leaks. World J Gastrointest Endosc. 2013 Jul 16;5(7):332-9. doi: 10.4253/wjge.v5.i7.332. PMID: 23858377; PMCID: PMC3711064.
Copy Download .nbib Format: NLM
Nonoperative management of complicated hiatal hernia after transhiatal esophagectomy- case report.

Annals of medicine and surgery (2012)

Lalezari S, Hanak CR, Husted T.
PMID: 30101007
Ann Med Surg (Lond). 2018 Jul 24;33:13-15. doi: 10.1016/j.amsu.2018.07.007. eCollection 2018 Sep.

INTRODUCTION: Hiatal hernia is rare after transhiatal esophagectomy occurring in less than 2% of patients [5]. Due to the rare incidence of hiatal hernias after transhiatal esophagectomy overlooking this differential in a symptomatic patient can be problematic. Patients can...

Cite
Lalezari S, Hanak CR, Husted T. Nonoperative management of complicated hiatal hernia after transhiatal esophagectomy- case report. Ann Med Surg (Lond). 2018;33:13-15doi: 10.1016/j.amsu.2018.07.007.
Lalezari, S., Hanak, C. R., & Husted, T. (2018). Nonoperative management of complicated hiatal hernia after transhiatal esophagectomy- case report. Annals of medicine and surgery (2012), 3313-15. https://doi.org/10.1016/j.amsu.2018.07.007
Lalezari, Sepher, et al. "Nonoperative management of complicated hiatal hernia after transhiatal esophagectomy- case report." Annals of medicine and surgery (2012) vol. 33 (2018): 13-15. doi: https://doi.org/10.1016/j.amsu.2018.07.007
Lalezari S, Hanak CR, Husted T. Nonoperative management of complicated hiatal hernia after transhiatal esophagectomy- case report. Ann Med Surg (Lond). 2018 Jul 24;33:13-15. doi: 10.1016/j.amsu.2018.07.007. eCollection 2018 Sep. PMID: 30101007; PMCID: PMC6083815.
Copy Download .nbib Format: NLM
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.

European urology open science

Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y, Kuusk T, Boleti E, Blank CU, Haanen JBAG, Powles T, Bex A.
PMID: 35024632
Eur Urol Open Sci. 2022 Jan 03;35:54-58. doi: 10.1016/j.euros.2021.11.003. eCollection 2022 Jan.

Following CARMENA and SURTIME, patients with metastatic renal cell carcinoma (mRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk receive systemic therapy with the primary tumour (primary) in place, with the option of deferred cytoreductive nephrectomy...

Cite
Meerveld-Eggink A, Graafland N, Wilgenhof S, et al. Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. Eur Urol Open Sci. 2022;35:54-58doi: 10.1016/j.euros.2021.11.003.
Meerveld-Eggink, A., Graafland, N., Wilgenhof, S., Van Thienen, J. V., Lalezari, F., Grant, M., Szabados, B., Abu-Ghanem, Y., Kuusk, T., Boleti, E., Blank, C. U., Haanen, J. B. A. G., Powles, T., & Bex, A. (2022). Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. European urology open science, 3554-58. https://doi.org/10.1016/j.euros.2021.11.003
Meerveld-Eggink, Aafke, et al. "Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment." European urology open science vol. 35 (2022): 54-58. doi: https://doi.org/10.1016/j.euros.2021.11.003
Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y, Kuusk T, Boleti E, Blank CU, Haanen JBAG, Powles T, Bex A. Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. Eur Urol Open Sci. 2022 Jan 03;35:54-58. doi: 10.1016/j.euros.2021.11.003. eCollection 2022 Jan. PMID: 35024632; PMCID: PMC8738899.
Copy Download .nbib Format: NLM
Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study.

American journal of ophthalmology case reports

Chan CK, Sarraf D, Abraham P, Lalezary M, Lin SG, Chen X, Nittala MG, Sadda S.
PMID: 33024885
Am J Ophthalmol Case Rep. 2020 Sep 18;20:100916. doi: 10.1016/j.ajoc.2020.100916. eCollection 2020 Dec.

PURPOSE: This prospective case series investigates the visual and anatomical outcomes including detailed volumetrics of eyes with vascularized pigment epithelial detachments (PED) treated with aflibercept in eyes with neovascular age-related macular degeneration (nAMD) through meticulous analysis in a reading...

Cite
Chan CK, Sarraf D, Abraham P, et al. Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study. Am J Ophthalmol Case Rep. 2020;20:100916doi: 10.1016/j.ajoc.2020.100916.
Chan, C. K., Sarraf, D., Abraham, P., Lalezary, M., Lin, S. G., Chen, X., Nittala, M. G., & Sadda, S. (2020). Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study. American journal of ophthalmology case reports, 20100916. https://doi.org/10.1016/j.ajoc.2020.100916
Chan, Clement K, et al. "Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study." American journal of ophthalmology case reports vol. 20 (2020): 100916. doi: https://doi.org/10.1016/j.ajoc.2020.100916
Chan CK, Sarraf D, Abraham P, Lalezary M, Lin SG, Chen X, Nittala MG, Sadda S. Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study. Am J Ophthalmol Case Rep. 2020 Sep 18;20:100916. doi: 10.1016/j.ajoc.2020.100916. eCollection 2020 Dec. PMID: 33024885; PMCID: PMC7527713.
Copy Download .nbib Format: NLM
A Call to Arms: Emergency Hand and Upper-Extremity Operations During the COVID-19 Pandemic.

Journal of hand surgery global online

Diamond S, Lundy JB, Weber EL, Lalezari S, Rafijah G, Leis A, Gray BL, Lin IC, Gupta R.
PMID: 32835183
J Hand Surg Glob Online. 2020 Jul;2(4):175-181. doi: 10.1016/j.jhsg.2020.05.004. Epub 2020 May 29.

PURPOSE: Limited data exist regarding volumetric trends and management of upper-extremity emergencies during periods of social restriction and duress, such as the coronavirus disease 2019 pandemic. We sought to study the effect of shelter-in-place orders on emergent operative upper-extremity...

Cite
Diamond S, Lundy JB, Weber EL, et al. A Call to Arms: Emergency Hand and Upper-Extremity Operations During the COVID-19 Pandemic. J Hand Surg Glob Online. 2020;2(4):175-181doi: 10.1016/j.jhsg.2020.05.004.
Diamond, S., Lundy, J. B., Weber, E. L., Lalezari, S., Rafijah, G., Leis, A., Gray, B. L., Lin, I. C., & Gupta, R. (2020). A Call to Arms: Emergency Hand and Upper-Extremity Operations During the COVID-19 Pandemic. Journal of hand surgery global online, 2(4), 175-181. https://doi.org/10.1016/j.jhsg.2020.05.004
Diamond, Shawn, et al. "A Call to Arms: Emergency Hand and Upper-Extremity Operations During the COVID-19 Pandemic." Journal of hand surgery global online vol. 2,4 (2020): 175-181. doi: https://doi.org/10.1016/j.jhsg.2020.05.004
Diamond S, Lundy JB, Weber EL, Lalezari S, Rafijah G, Leis A, Gray BL, Lin IC, Gupta R. A Call to Arms: Emergency Hand and Upper-Extremity Operations During the COVID-19 Pandemic. J Hand Surg Glob Online. 2020 Jul;2(4):175-181. doi: 10.1016/j.jhsg.2020.05.004. Epub 2020 May 29. PMID: 32835183; PMCID: PMC7256509.
Copy Download .nbib Format: NLM
Oxysterols as promising small molecules for bone tissue engineering: Systematic review.

World journal of orthopedics

Cottrill E, Lazzari J, Pennington Z, Ehresman J, Schilling A, Dirckx N, Theodore N, Sciubba D, Witham T.
PMID: 32908817
World J Orthop. 2020 Jul 18;11(7):328-344. doi: 10.5312/wjo.v11.i7.328. eCollection 2020 Jul 18.

BACKGROUND: Bone tissue engineering is an area of continued interest within orthopaedic surgery, as it promises to create implantable bone substitute materials that obviate the need for autologous bone graft. Recently, oxysterols - oxygenated derivatives of cholesterol - have...

Cite
Cottrill E, Lazzari J, Pennington Z, et al. Oxysterols as promising small molecules for bone tissue engineering: Systematic review. World J Orthop. 2020;11(7):328-344doi: 10.5312/wjo.v11.i7.328.
Cottrill, E., Lazzari, J., Pennington, Z., Ehresman, J., Schilling, A., Dirckx, N., Theodore, N., Sciubba, D., & Witham, T. (2020). Oxysterols as promising small molecules for bone tissue engineering: Systematic review. World journal of orthopedics, 11(7), 328-344. https://doi.org/10.5312/wjo.v11.i7.328
Cottrill, Ethan, et al. "Oxysterols as promising small molecules for bone tissue engineering: Systematic review." World journal of orthopedics vol. 11,7 (2020): 328-344. doi: https://doi.org/10.5312/wjo.v11.i7.328
Cottrill E, Lazzari J, Pennington Z, Ehresman J, Schilling A, Dirckx N, Theodore N, Sciubba D, Witham T. Oxysterols as promising small molecules for bone tissue engineering: Systematic review. World J Orthop. 2020 Jul 18;11(7):328-344. doi: 10.5312/wjo.v11.i7.328. eCollection 2020 Jul 18. PMID: 32908817; PMCID: PMC7453739.
Copy Download .nbib Format: NLM
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.

medRxiv : the preprint server for health sciences

Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari JP, Pang AP, Sugai C, Francisco EB, Pise A, Rodrigues H, Ryou M, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Aklin E, Ndhlovu L, Sacha JB.
PMID: 32511656
medRxiv. 2020 May 05; doi: 10.1101/2020.05.02.20084673.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is now pandemic with nearly three million cases reported to date. Although the majority of COVID-19 patients experience only mild or moderate symptoms, a...

Cite
Patterson BK, Seethamraju H, Dhody K, et al. Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. medRxiv. 2020;doi: 10.1101/2020.05.02.20084673.
Patterson, B. K., Seethamraju, H., Dhody, K., Corley, M. J., Kazempour, K., Lalezari, J. P., Pang, A. P., Sugai, C., Francisco, E. B., Pise, A., Rodrigues, H., Ryou, M., Wu, H. L., Webb, G. M., Park, B. S., Kelly, S., Pourhassan, N., Lelic, A., Kdouh, L., Herrera, M., Hall, E., Aklin, E., Ndhlovu, L., & Sacha, J. B. (2020). Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.05.02.20084673
Patterson, Bruce K, et al. "Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.05.02.20084673
Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari JP, Pang AP, Sugai C, Francisco EB, Pise A, Rodrigues H, Ryou M, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Aklin E, Ndhlovu L, Sacha JB. Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. medRxiv. 2020 May 05; doi: 10.1101/2020.05.02.20084673. PMID: 32511656; PMCID: PMC7277012.
Copy Download .nbib Format: NLM
Patient Race and Provider Predict Patient Satisfaction Following Post-Mastectomy Breast Reconstruction.

World journal of plastic surgery

Shaterian A, Gandy J, Lalezari S, Smith S, Paydar K.
PMID: 27579266
World J Plast Surg. 2016 May;5(2):114-23.

BACKGROUND: Post-mastectomy breast reconstruction is commonly performed in the United States with numerous options available to patients and providers. This study evaluated patient race and provider in prediction of patient satisfaction following post-mastectomy breast reconstruction.METHODS: The patient satisfaction for...

Cite
Shaterian A, Gandy J, Lalezari S, et al. Patient Race and Provider Predict Patient Satisfaction Following Post-Mastectomy Breast Reconstruction. World J Plast Surg. 2016;5(2):114-23
Shaterian, A., Gandy, J., Lalezari, S., Smith, S., & Paydar, K. (2016). Patient Race and Provider Predict Patient Satisfaction Following Post-Mastectomy Breast Reconstruction. World journal of plastic surgery, 5(2), 114-23.
Shaterian, Ashkaun, et al. "Patient Race and Provider Predict Patient Satisfaction Following Post-Mastectomy Breast Reconstruction." World journal of plastic surgery vol. 5,2 (2016): 114-23.
Shaterian A, Gandy J, Lalezari S, Smith S, Paydar K. Patient Race and Provider Predict Patient Satisfaction Following Post-Mastectomy Breast Reconstruction. World J Plast Surg. 2016 May;5(2):114-23. PMID: 27579266; PMCID: PMC5003946.
Copy Download .nbib Format: NLM
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.

Nature cancer

Anagnostou V, Niknafs N, Marrone K, Bruhm DC, White JR, Naidoo J, Hummelink K, Monkhorst K, Lalezari F, Lanis M, Rosner S, Reuss JE, Smith KN, Adleff V, Rodgers K, Belcaid Z, Rhymee L, Levy B, Feliciano J, Hann CL, Ettinger DS, Georgiades C, Verde F, Illei P, Li QK, Baras AS, Gabrielson E, Brock MV, Karchin R, Pardoll DM, Baylin SB, Brahmer JR, Scharpf RB, Forde PM, Velculescu VE.
PMID: 32984843
Nat Cancer. 2020 Jan;1(1):99-111. doi: 10.1038/s43018-019-0008-8. Epub 2020 Jan 13.

Despite progress in immunotherapy, identifying patients that respond has remained a challenge. Through analysis of whole-exome and targeted sequence data from 5,449 tumors, we found a significant correlation between tumor mutation burden (TMB) and tumor purity, suggesting that low...

Cite
Anagnostou V, Niknafs N, Marrone K, et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer. 2020;1(1):99-111doi: 10.1038/s43018-019-0008-8.
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., Rosner, S., Reuss, J. E., Smith, K. N., Adleff, V., Rodgers, K., Belcaid, Z., Rhymee, L., Levy, B., Feliciano, J., Hann, C. L., Ettinger, D. S., Georgiades, C., Verde, F., Illei, P., Li, Q. K., Baras, A. S., Gabrielson, E., Brock, M. V., Karchin, R., Pardoll, D. M., Baylin, S. B., Brahmer, J. R., Scharpf, R. B., Forde, P. M., & Velculescu, V. E. (2020). Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature cancer, 1(1), 99-111. https://doi.org/10.1038/s43018-019-0008-8
Anagnostou, Valsamo, et al. "Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer." Nature cancer vol. 1,1 (2020): 99-111. doi: https://doi.org/10.1038/s43018-019-0008-8
Anagnostou V, Niknafs N, Marrone K, Bruhm DC, White JR, Naidoo J, Hummelink K, Monkhorst K, Lalezari F, Lanis M, Rosner S, Reuss JE, Smith KN, Adleff V, Rodgers K, Belcaid Z, Rhymee L, Levy B, Feliciano J, Hann CL, Ettinger DS, Georgiades C, Verde F, Illei P, Li QK, Baras AS, Gabrielson E, Brock MV, Karchin R, Pardoll DM, Baylin SB, Brahmer JR, Scharpf RB, Forde PM, Velculescu VE. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer. 2020 Jan;1(1):99-111. doi: 10.1038/s43018-019-0008-8. Epub 2020 Jan 13. PMID: 32984843; PMCID: PMC7514475.
Copy Download .nbib Format: NLM
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.

Journal of translational autoimmunity

Elneil S, Lalezari JP, Pourhassan NZ.
PMID: 33778462
J Transl Autoimmun. 2021;4:100097. doi: 10.1016/j.jtauto.2021.100097. Epub 2021 Mar 23.

The number of confirmed cases of infection with SARS-CoV-2, the virus causing Coronavirus disease 2019 (COVID-19), continues to increase and is associated with substantial morbidity and mortality in virtually every country in the world. Although in the long-term mass...

Cite
Elneil S, Lalezari JP, Pourhassan NZ. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab. J Transl Autoimmun. 2021;4:100097doi: 10.1016/j.jtauto.2021.100097.
Elneil, S., Lalezari, J. P., & Pourhassan, N. Z. (2021). Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab. Journal of translational autoimmunity, 4100097. https://doi.org/10.1016/j.jtauto.2021.100097
Elneil, Sohier, et al. "Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab." Journal of translational autoimmunity vol. 4 (2021): 100097. doi: https://doi.org/10.1016/j.jtauto.2021.100097
Elneil S, Lalezari JP, Pourhassan NZ. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab. J Transl Autoimmun. 2021;4:100097. doi: 10.1016/j.jtauto.2021.100097. Epub 2021 Mar 23. PMID: 33778462; PMCID: PMC7985604.
Copy Download .nbib Format: NLM
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Nature medicine

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.
PMID: 31209337
Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

In the version of this article originally published, there was an error in Fig. 3j. A label on the heatmap read "TGF-α signaling via NF-κB". It should have read "TNF-α signaling via NF-κB". The error has been corrected in...

Cite
Voorwerk L, Slagter M, Horlings HM, et al. Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(7):1175doi: 10.1038/s41591-019-0520-5.
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., Wiersma, T. G., Russell, N. S., Lalezari, F., Schouten, P. C., Bakker, N. A. M., Ketelaars, S. L. C., Peters, D., Lange, C. A. H., van Werkhoven, E., van Tinteren, H., Mandjes, I. A. M., Kemper, I., Onderwater, S., Chalabi, M., Wilgenhof, S., Haanen, J. B. A. G., Salgado, R., de Visser, K. E., Sonke, G. S., Wessels, L. F. A., Linn, S. C., Schumacher, T. N., Blank, C. U., & Kok, M. (2019). Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature medicine, 25(7), 1175. https://doi.org/10.1038/s41591-019-0520-5
Voorwerk, Leonie, et al. "Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial." Nature medicine vol. 25,7 (2019): 1175. doi: https://doi.org/10.1038/s41591-019-0520-5
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5. PMID: 31209337.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 38 entries